(R)-tert-butyl 3-(methyl(5-(methylsulfonyl)pyridin-2-yl)amino)pyrrolidine-1-carboxylate | 1360095-76-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (R)-tert-butyl 3-(methyl(5-(methylsulfonyl)pyridin-2-yl)amino)pyrrolidine-1-carboxylate
• 英文别名: tert-butyl (3R)-3-[methyl-(5-methylsulfonylpyridin-2-yl)amino]pyrrolidine-1-carboxylate
• CAS: 1360095-76-6
• 化学式: C₁₆H₂₅N₃O₄S
• 分子量: 355.458
• InChiKey: HAJOMISLUBCYLD-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  88.2
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PYRROLOPYRIMIDINE ET LEURS UTILISATIONS
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2012022265A1

  公开（公告）日：2012-02-23

  Disclosed are pyrrolopyrimidine compounds of formula (I) capable of inhibiting JAK kinase, wherein R1, R2 and m are defined as in the description. The pharmaceutical compositions containing said pyrrolopyrimidine compounds and uses of said pyrrolopyrimidine compounds in the treatment of disorders or diseases such as inflammatory diseases and cancers are also disclosed.

  公开了具有以下式（I）的吡咯吡嘧啶化合物，能够抑制JAK激酶，其中R1、R2和m的定义如描述中所述。还公开了含有所述吡咯吡嘧啶化合物的药物组合物，以及所述吡咯吡嘧啶化合物在治疗炎症性疾病和癌症等疾病或疾病中的用途。
• PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：HUTCHISON MEDIPHARMA LIMITED

  公开号：US20160228443A1

  公开（公告）日：2016-08-11

  The present disclosure provides pyrrolopyrimidine compounds and methods of use therefor. For example, the disclosure provides certain pyrrolopyrimidine compounds capable of inhibiting JAK kinases. The disclosure further provides the pharmaceutical compositions containing these pyrrolopyrimidine compounds, and use of these pyrrolopyrimidine compounds in the treatment of disorders or diseases, such as inflammatory diseases and cancer.

  本文提供了吡咯并嘧啶化合物及其使用方法。例如，本文提供了某些能够抑制JAK激酶的吡咯并嘧啶化合物。本文还提供了含有这些吡咯并嘧啶化合物的制药组合物，并将这些吡咯并嘧啶化合物用于治疗炎症性疾病和癌症等疾病或疾病的方法。
• Pyrrolopyrimidine compounds and uses thereof
  申请人：HUTCHISON MEDIPHARMA LIMITED

  公开号：US10369153B2

  公开（公告）日：2019-08-06

  The present disclosure provides pyrrolopyrimidine compounds and methods of use therefor. For example, the disclosure provides certain pyrrolopyrimidine compounds capable of inhibiting JAK kinases. The disclosure further provides the pharmaceutical compositions containing these pyrrolopyrimidine compounds, and use of these pyrrolopyrimidine compounds in the treatment of disorders or diseases, such as inflammatory diseases and cancer.

  本公开提供了吡咯并嘧啶化合物及其使用方法。例如，本公开提供了某些能够抑制 JAK 激酶的吡咯并嘧啶化合物。本公开进一步提供了含有这些吡咯并嘧啶化合物的药物组合物，以及这些吡咯并嘧啶化合物在治疗紊乱或疾病（如炎症性疾病和癌症）中的用途。